



Received on 24 November 2018; received in revised form, 12 June 2019; accepted, 21 June 2019; published 01 August 2019

## PRELIMINARY PHYTOCHEMICAL INVESTIGATIONS AND ANTI-EPILEPTIC ACTIVITY OF *TREMA ORIENTALIS* (LINN.) EXTRACTS

K. M. Geetha<sup>\*</sup>, K. Vishnupriya, Fareshteh Jaferi and V. Murugan

Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore - 560078, Karnataka, India.

### Keywords:

Anti-epileptic,  
*Trema orientalis*, Lupeol,  
Brain GABA

### Correspondence to Author:

**Dr. K. M. Geetha**

Professor,  
Department of Pharmacology,  
College of Pharmaceutical Sciences,  
Dayananda Sagar University,  
Bangalore - 560078, Karnataka, India.

**E-mail:** geethakm@yahoo.com

**ABSTRACT: Objective:** The antiepileptic potential of the petroleum ether (PETO) and methanolic extracts (METO) of the whole plant (roots, leaves, stem, and bark) of *Trema orientalis* (family: Ulmaceae) was evaluated using different experimental models of epilepsy in rats and mice. **Materials and Methods:** The anti-epileptic activity of the PETO and METO was evaluated using Picrotoxin, Isoniazid, and NMDA induced convulsion models. The brain GABA was also estimated in Picrotoxin induced convulsion model. The amount of the Lupeol present in PETO was estimated by HPTLC. **Results:** Preliminary phytochemical screening of the extracts revealed the presence of phytosterols, triterpenoids, Fixed oils & Fats, Tannins, phenolics, flavonoids, and carbohydrates. The anti-epileptic activity of PETO and METO at doses of 250 mg/kg and 500 mg/kg showed a significant increase ( $p < 0.001$ ) in the onset of convulsions in the models used. The extracts also showed a significant increase in the brain GABA levels in the doses used. The amount of lupeol present in PETO was estimated to be 8.76  $\mu\text{g/ml}$ . **Conclusion:** The PETO and METO showed significant anti-epileptic activity in the doses used mediated through an increase in the brain GABA levels.

**INTRODUCTION:** Epilepsy is a disorder of the brain that affects many people around the world and is characterized by recurrent unprovoked seizures<sup>1</sup>. These seizures are indicative of symptoms of high neuronal activity in the brain. It is characterized by an enduring predisposition to generate epileptic seizures by the neurobiological and psychological consequences of this condition<sup>2</sup>. The antiepileptic drugs that are presently available are unable to control seizures effectively in as many as 25% of the patients<sup>3, 4</sup>. The conventionally available antiepileptic agents like phenytoin, carbamazepine, and sodium valproate have several side effects like neurotoxicity and sedation<sup>5</sup>.

As the majority of antiepileptic drugs are consumed life long, concomitant administration of other drugs predisposes to the risk of a drug interaction. Thus, an investigation of a safe antiepileptic agent that is highly efficacious and less toxic is necessary.

The medicinal herb, *Trema orientalis* (Linn.) Blume belonging to the family, Ulmaceae, is a shrub or small to medium size tree and its height varies depending on the location and climatic conditions. It can grow up to 18 m high in forest regions, and up to 1.5 m tall in the savannah. The slender branchlets are covered with white velvety hairs<sup>6</sup>. The young leaves are consumed by the Zulus in South Africa, and the fruits and leaves are also used for its medicinal value<sup>7, 8</sup>. The root of *T. orientalis* is used in folk medicine for the treatment of trauma, blood stasis, hematuria, and bleeding of intestines and stomach<sup>9</sup>. The stem bark decoctions are used as a vermifuge and anti-dysenteries<sup>10</sup>. The stems and twigs infusion are used to treat fever and toothache.

<p><b>QUICK RESPONSE CODE</b></p> 	<p><b>DOI:</b> 10.13040/IJPSR.0975-8232.10(8).3957-62</p> <hr/> <p>This article can be accessed online on <a href="http://www.ijpsr.com">www.ijpsr.com</a></p>
<p><b>DOI link:</b> <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.10(8).3957-62">http://dx.doi.org/10.13040/IJPSR.0975-8232.10(8).3957-62</a></p>	

Both stem bark and leaf decoction of the *T. orientalis* is used to treat malaria, manage pain in tired muscles and aching bones as well as venereal disease<sup>11</sup>. The leaf of *T. orientalis* is mixed with leaves of *Bidens pilosa*, *Citrus aurantifolia*, and peels of unripe pineapple. It is boiled and the decoction used in the management of jaundice<sup>12</sup>. The leaves macerated in lemon juice are used as a remedy for bronchitis, pneumonia and pleurisy<sup>13</sup>.

## MATERIALS AND METHODS:

**Chemicals and Reagents:** All chemicals, standard drugs and solvents like Petroleum ether, chloroform, ethanol, picrotoxin, isoniazid, n-methyl d-aspartate, dizocilpine hydrogen maleate (MK-801), standard gamma-Aminobutyric acid, trichloroacetic acid, Ninhydrin, sodium carbonate, sodium Bicarbonate, di-sodium carbonate, copper sulphate, tartaric acid and Glutamic acid were of analytical grade and obtained commercially.

**Collection and Authentication:** For the whole study plant of *Trema orientalis* L. Blume was collected from Tirupati, Chittoor district, Andhra Pradesh, India in the month of June-July matching its seasonal availability. The plant was identified and authenticated (Voucher no. 2307), and the voucher specimen was also deposited for future reference.

**Preparation of the Plant Extract:** Dried and whole powdered plant of *Trema orientalis* (1000 g) were subjected to successive solvent extraction in a Soxhlet extractor using the solvents petroleum ether, chloroform, and methanol. The extracts were vacuum dried using rotary evaporator. The weight of the dried extracts was Petroleum ether (28.32 g), chloroform (19.78 g) and methanol (72.89 g). The percentage yield of Petroleum ether chloroform and methanol extracts were 2.8%, 1.9%, and 7.2% respectively.

**Phytochemical Screening:** Preliminary Phytochemical screening of the extracts of the whole plant of *T. orientalis* was carried out using standard procedures<sup>14,15</sup>.

**Animals:** Albino rats (Wistar strain) and Swiss Albino mice of either sex weighing 180-220 g and 18-22 g respectively were procured from the animal house of Dayananda Sagar University and were acclimatized for seven days under laboratory

conditions. The study protocols were duly approved by the Institutional Animal Ethics Committee bearing Approval no. DSCP/M Pharm/IAEC/03/16-17. Studies were performed by the CPCSEA guidelines.

**Acute Toxicity:** Toxicity study of PETO and METO was determined according to the OECD guidelines No. 423. All treated animals were monitored for at least twice daily for behavioral and mortality changes.

**Picrotoxin Induced Convulsions:** Albino mice (18-22 g) of either sex were divided into 6 groups of six rats each and was fasted overnight before the test, but the water was supplied *ad libitum*. Group I was maintained as control which was given normal saline p.o. once daily for 7 days. On 7<sup>th</sup> day 60 min after administration, picrotoxin (7 mg/kg *i.p.*) was administered. Group II was administered with diazepam (4 mg/kg *i.p.*) alone on 1<sup>st</sup> day, and 30 min after administration (diazepam) picrotoxin was administered. Groups III & IV are treated with different doses of PETO (250 and 500 mg/kg *p.o.*) and Group V & VI were treated with different doses of METO (250 and 500 mg/kg *p.o.*) respectively once daily for 7 days.

On 7<sup>th</sup> day 60 min after administration of the test extracts, picrotoxin was administered. The animals were observed for the onset of convulsions<sup>16,17,18</sup>.

**Isoniazid Induced Convulsions:** Albino mice (18-22 g) of either sex were divided into 6 groups of six rats each and was fasted overnight before the test, but the water was supplied *ad libitum*. Group I was maintained as control and was given normal saline p.o. once daily for 7 days. On the 7<sup>th</sup> day, 60 min after administration of saline, isoniazid (250 mg/kg *i.p.*) was administered. Group II was administered diazepam (4 mg/kg *i.p.*) alone on 1<sup>st</sup> day, and 30 min after administration (diazepam) isoniazid was administered. Groups III & IV were treated with different doses of PETO (250 and 500 mg/kg *p.o.*), and Group V & VI were treated with different doses of METO (250 and 500 mg/kg *p.o.*) respectively once daily for 7 days.

On the 7<sup>th</sup> day 60 min after the administration of extracts, isoniazid was administered. The animals were observed for the onset of convulsions<sup>18,19,20</sup>.

**NMDA Induced Seizures:** Albino mice (18-22 g) of either sex was divided into 6 groups of six rats each and was fasted overnight before the test, but the water was supplied *ad libitum*. Group I was maintained as control which was given normal saline p.o. once daily for 7 days. On 7<sup>th</sup> day, 60 min after administration, NMDA (100 mg/kg i.p.) was administered. Group II was administered Dizocipine hydrogen maleate 0.05 mg/kg (i.p) alone on 1<sup>st</sup> day, and 30 min later, NMDA was administered. Groups III & IV were treated with different doses of PETO (250 and 500 mg/kg p.o.), and Group V & VI were treated with different doses of METO (250 and 500 mg/kg p.o.) respectively once daily for 7 days. On 7<sup>th</sup> day 60 min after extract administration. The animals were observed for turning behavior within 30 min, which was characterized by two consecutive 360° cycles fulfilled by the same animal<sup>21, 22</sup>.

**Estimation of Brain GABA Content:** The brain aminobutyric acid (GABA) content was estimated in picrotoxin induced model. Animals were sacrificed by decapitation, and brains were rapidly removed and separated forebrain region. It was blotted, weighed and placed in 5 ml of ice-cold trichloroacetic acid (10% w/v), then homogenized and centrifuged at 10,000 rpm for 10 min at 0 °C. A sample (0.1 ml) of tissue extract was placed in 0.2 ml of 0.14 M ninhydrin solution in 0.5M carbonate-bicarbonate buffer (pH 9.95), kept in a water bath at 60 °C for 30 min, then cooled and treated with 5 ml of copper tartrate reagent (0.16% disodium carbonate, 0.03% copper sulphate and 0.0329% tartaric acid). After 10 min fluorescence at 377/455 nm in a spectrofluorimeter was recorded<sup>23, 24</sup>.

**Estimation of Lupeol in PETO by HPTLC:** *Trema orientalis* contains Lupeol which is reported to possess anticonvulsant activity<sup>25</sup>. Hence, HPTLC method was used to quantify the amount of lupeol content in PETO. The petroleum ether extracts were filtered and dissolved in ethanol and subjected to HPTLC analysis. Chromatography was performed on 20 cm × 20 cm aluminum packed HPTLC plates coated with 0.2 mm layers of silica gel - 60 F254. A working standard of 1 mg/ml solution of lupeol was prepared and used as the reference standard. The chromatogram was developed up to 70 mm under chamber saturation

conditions using Toluene: Methanol (9:1.5 v/v) as a solvent system in Camag twin trough chamber. The developed plates were photo-documented at 254 nm, and the amount of lupeol present in PETO was quantified using the standard formula.

**Statistical Analysis:** Values were expressed as mean ± SEM. The experimental mean values were compared statistically with that of vehicle control using One Way Analysis of Variance (ANOVA) followed Dunnett's multiple comparison test. The analysis was carried out using Graph Pad Prism software V.7.p values less than 0.5 were considered to be statistically significant.

## RESULTS:

**Phytochemical Screening:** The Petroleum ether extract showed the presence of phytosterols, triterpenoids, Fixed oils & Fats, while Methanolic extract showed the presence of Tannins & phenolics, flavonoids, and carbohydrates but chloroform extract did not show any phytoconstituents.

**Acute Toxicity Studies:** An acute toxicity study of PETO & METO was determined in rats, as per OECD guidelines no. 423 and the extracts produced no mortality up to 2000 mg/kg.

**Effect of PETO and METO on Picrotoxin Induced Convulsions in Rats:** Administration of picrotoxin at 7 mg/kg, i.p. produced convulsions and death in rats. Pretreatment with standard drug diazepam exhibited anticonvulsant effect by increased time for onset of convulsion and offered 66% protection. The low dose of PETO showed no significant activity, but the high dose showed increased time in the onset of convulsion with no protection whereas both the doses of METO showed a significant increase in onset of convulsions with the % protection of 16.66% and 33.33% respectively **Table 1**.

**Effect of PETO and METO on Isoniazid Induced Convulsions in Rats:** Administration of isoniazid at 250 mg/kg, i.p. produced significant convulsions in rats. No convulsions were recorded with diazepam and it showed 100% protection in rats. Pretreatment with low and high doses of both PETO and METO showed anticonvulsant effect by increasing the time in the onset of tonic convulsion and showed protection up to 100% in all the animal's **Table 2**.

**TABLE 1: EFFECT OF PETO AND METO ON PICROTOXIN INDUCED CONVULSIONS IN RATS**

Groups no.	Treatment	Dose (mg/kg)	Onset of Convulsions (min)	Status of Animal (No of Animal alive)	% Protection
Group I	Control (Vehicle)	-	5.35 ± 0.43	0	0
Group II	Diazepam	4	16.01 ± 0.57***	4	66.66
Group III	PETO	250	6.77 ± 1.96 <sup>ns</sup>	0	0
Group IV	PETO	500	9.91 ± 0.50**	0	0
Group V	METO	250	10.43 ± 0.79**	1	16.66
Group VI	METO	500	17.19 ± 1.17***	2	33.33

Values are mean ± S.E.M (n=6), ANOVA followed by Dunnet's Multiple Comparison test. Where \*\*\* represents very significant at p<0.001, \*\* represents significant at p<0.01 and ns represents non-significant.

**TABLE 2: EFFECT OF PETO AND METO ON ISONIAZID INDUCED CONVULSIONS IN RATS**

Groups no.	Treatment	Dose (mg/kg)	Onset of Convulsions (min)	Status of Animal (No of Animal alive)	% Protection
Group I	Control (Vehicle)	-	23.75 ± 2.39	0	0
Group II	Diazepam	4	78.5 ± 1.49***	6	100
Group III	PETO	250	46.25 ± 2.39*	6	100
Group IV	PETO	500	65 ± 4.56***	6	100
Group V	METO	250	67.75 ± 8.89***	6	100
Group VI	METO	500	72.5 ± 5.95***	6	100

Values are mean ± S.E.M (n=6), ANOVA followed by Dunnet's Multiple Comparison test. Where \*\*\* represents very significant at p<0.001 and \* represents significant at p<0.05.

**Effect of PETO and METO on NMDA-Induced Seizures in Mice:** Administration of NMDA at 100 mg/kg, i.p. showed significant turning behavior in mice. Pretreatment with standard (Dizocilpine hydrogen maleate) significantly antagonized NMDA- induced turning behavior in the animals

but showed only 66.66% of protection. The low and high doses of METO significantly antagonized turning behavior with 100% protection, whereas in PETO, it was not significant at both the doses with no protection **Table 3**.

**TABLE 3: EFFECT OF PETO AND METO ON NMDA-INDUCED SEIZURES IN MICE**

Groups no.	Treatment	Dose (mg/kg)	Onset of Convulsions (min)	Status of Animal (No of Animal alive)	% Protection
Group I	Control (Vehicle)	-	7.35 ± 1.25	0	0
Group II	Dizocilpine hydrogen maleate	0.05	32.5 ± 2.5***	4	66.66
Group III	PETO	250	6.75 ± 2.92 <sup>ns</sup>	0	0
Group IV	PETO	500	12.5 ± 3.12 <sup>ns</sup>	0	0
Group V	METO	250	37.20 ± 2.60***	6	100
Group VI	METO	500	42.5 ± 3.62***	6	100

Values are mean ± S.E.M (n=6), ANOVA followed by Dunnet's Multiple Comparison test. Where \*\*\* represents very significant at p<0.001 and ns represents non-significant.

**Estimation of Brain GABA:** The brain GABA level was estimated in picrotoxin induced convulsion model. Pretreatment with standard diazepam significantly increased GABA levels in

the serum. Low and high doses of PETO and METO treated groups showed a significant increase in GABA levels of the animal's **Table 4**.

**TABLE 4: ESTIMATION OF BRAIN GABA LEVELS**

Groups no.	Treatment	Dose (mg/kg)	Concentration of GABA (µg)
Group I	Control (Vehicle)	-	28.24 ± 1.61
Group II	Diazepam	4	76.99 ± 2.44***
Group III	PETO	250	40.75 ± 1.89**
Group IV	PETO	500	64.04 ± 2.73***
Group V	METO	250	69.37 ± 3.13***
Group VI	METO	500	83.17 ± 2.42***


Values are mean ± S.E.M (n=6), ANOVA followed by Dunnet's Multiple Comparison test. Where \*\*\* represents very significant at p<0.001 and \*\* represents significant at p<0.01.

**Estimation of Lupeol in PETO by HPTLC:**  $R_f$  value of standard Lupeol was found to be 0.47, and the peak area was found to be 12744.6. PETO showed six peaks, and the fourth peak with an  $R_f$


value of 0.46 was coinciding with standard  $R_f$  value, and the peak area was 11394.8. Hence, the amount of Lupeol present in PETO was found to be 8.76  $\mu\text{g/ml}$  **Table 5, Fig. 1a and 1b.**

**TABLE 5: ESTIMATION OF LUPEOL IN PETO BY HPTLC**

S. no.	Sample	Start $R_f$ value	Area (AU)	Dilution	Concentration ( $\mu\text{g/ml}$ )
1	Standard Lupeol	0.47	12744.6	100	-
2	PETO	0.46	11394.8	10	8.76



**FIG. 1A: HPTLC PROFILE OF LUPEOL AT 254 nm**



**FIG. 1B: HPTLC PROFILE OF PET ETHER EXTRACT OF TREMAS ORIENTALIS AT 254 nm**

**DISCUSSION:** Epilepsy is a common chronic neurological disorder, and it imposes the biggest burden on health care systems. Deaths are likely to be caused by the background etiology of epilepsy, e.g., tumors, trauma, degenerative conditions, or cerebrovascular diseases. INH is commonly used for the treatment of TB but can have adverse effects on the CNS, causing seizures and comas<sup>26</sup>. INH induced seizures resemble symptoms of petitmal epilepsy. Gamma-aminobutyric acid (GABA) is the predominant inhibitory neurotransmitter in the CNS.

GABA is synthesized from the glutamate, exclusively in GABAergic neurons, by the action of the enzyme glutamic acid decarboxylase. The

convulsant activity of the INH is due to its effect on GABA-synthesis inhibitor, glutamic acid decarboxylase<sup>2, 27</sup>. The inhibitory effect of INH on the enzyme leads depletion of GABA concentration<sup>5</sup> and an increase in glutamate level in the brain. Depletion of GABA concentration resulted in a seizure. The PETO and METO at both low and high doses increased the onset of convulsions and showed 100% protection of the animals. Therefore the possible mechanism of the extracts may be due to increased GABA synthesis possibly by stimulation of L-Glutamate or by inhibition of GABA degradation by GABA transaminase<sup>28, 29</sup>.

Picrotoxin acts as a GABA<sub>A</sub>-antagonist by modifying the function of the chloride ion channel of the GABA<sub>A</sub> receptor complex<sup>19</sup>, and its GABA inhibitory actions affect different areas of the central nervous system. Although PETO and METO at different doses did not protect the animals against picrotoxin-induced convulsions and death, the fraction extended the mean onset of seizures, which indicates mild anticonvulsant activity against picrotoxin.

NMDA is an agonist that produces effects similar to glutamic acid at the NMDA receptors and exerts its convulsant effect by activating the receptors to enhance excitatory glutaminergic neurotransmission<sup>30, 31</sup>. NMDA-induced seizures in rodents have previously been proposed as a model of refractory seizures and are significantly suppressed by NMDA receptor antagonists<sup>32</sup>. The effects produced by METO suggest that the extract might be inhibitory against glutaminergic excitatory responses, specifically at the NMDA receptors<sup>33</sup>. The significant increase in the GABA concentration in the brain of animals were observed with low and high doses of the PETO, METO, and Diazepam treated groups, indicated that the extracts enhance the synthesis of GABA in GABAergic neurons.

**CONCLUSION:** The results obtained indicate that the extracts have significant anti-epileptic activity, which thus validates the traditional claims of *Trema orientalis*. The results of this study revealed that administration of extracts increased levels of GABA in the brain, showing that the actions were mediated by centrally acting mechanisms.

**ACKNOWLEDGEMENT:** The authors are grateful to Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka for funding this research work.

**CONFLICT OF INTEREST:** There is no conflict of interest among all authors in this study.

## REFERENCES:

- Goodman and Gilman. The Pharmacological basis of therapeutics. In: James O. McNamara Editors, Pharmacotherapy of Epilepsies, 11<sup>th</sup> Ed. New York: McGraw-Hill Publishers 2001: 501-25.
- Fisher RS, Van Emde Boas W, Blume W, Elger C, Genton P, Lee P and Engel J: Epileptic seizures and epilepsy: Definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia* 2005; 46(4): 470-2.
- Duraisami R, Seinivasan D and Ramasamy S: Anticonvulsant activity of bioflavonoid gossypin. *Bangladesh J Pharmacol* 2009; 4: 51-54.
- Mattson RH: Drug treatment of partial epilepsy. *Adv Neurol* 1992; 57: 643-50.
- Gupta YK and Malhotra J: Adenosinergic system as an endogenous anticonvulsant mechanism. *J Physio and Pharmacol* 1997; 41: 329-43.
- Smith CA: Pretoria: Department of Agricultural Technical Services. Common names of South African plants. *Memoirs of the Botanical Survey of SA* 1966: 35.
- Coates PK: 1<sup>st</sup> ed. Cape Town, Johannesburg: C. Struik Publishers Cape Town, Johannesburg. *Trees of Southern Africa* 1977.
- Iwu MM: Boca Raton, Florida: CRC Press Inc. *Handbook of African Medicinal Plants* 1993; 251-2.
- Hines DA and Eckman K: Ottawa Ontario Canada: Cultural Survival Canada and Development Services Foundation of Tanzania. *Indigenous multipurpose trees for Tanzania: Uses and economic benefits to the people* 1993; 26-27.
- Githens TS: African Handbooks. United States: University of Pennsylvania Press, Lancaster Press, Lancaster. *Drug plants of Africa* 1948; 8: 125-26.
- Rasoanaivo P, Petitjean A, Ratsimamanga-Urverg S and Rakoto-Ratsimamanga A: Medicinal plants used to treat malaria in Madagascar. *J Ethnopharmacol* 1992; 37: 117-27.
- Katende AB: Useful trees and shrubs for Uganda. Identification, Propagation and Management for Agricultural and Pastoral Communities. Regional Soil Conservation Unit (RSCU), Swedish International Development Authority (SIDA) 1995.
- Watt JM and Breyer-Brandwijk MG: 2<sup>nd</sup> ed. London: Livingstone. *The Medicinal and Poisonous Plants of Southern and Eastern Africa* 1962; 982-7.
- Khandelwal KR: Practical Pharmacognosy. Pune, Nirali Prakashan Publisher 2010: 23.
- Kokate CK: Practical Pharmacognosy. 4<sup>th</sup> Ed. New Delhi: Vallabh Prakashan Publisher 1994: 110-16.
- Aguiar CC, Almeida AB, Araújo PV, Vasconcelos GS and Chaves EM: Anticonvulsant effects of agomelatine in mice. *Epilepsy Behav* 2012; 24(3): 324-8.
- De Deyn PP, D'Hooge R, Marescau B and Pei YQ: Chemical models of epilepsy with some reference to their applicability in the development of anticonvulsants. *Epilepsy Res* 1992; 12(2): 87-110.
- Basavaraj P, Shivakumar B, Shivakumar H and Manjunath VJ: Evaluation of anticonvulsant activity of *T. divaricata* (Linn) R. Br. flower extract. *IJPPS* 2011; 3(3): 310-15.
- Gerhard-Vogel H and Wolf-Gang H: Drug discovery and evaluation pharmacological assays. 2<sup>nd</sup> ed., New York: Springer-Verlag Berlin Heidelberg Publisher 2002: 487- 94.
- Bonner AB, Peterson SL and Weir MR: Seizures induced by theophylline and isoniazid in mice. *Vet Hum Toxicol* 1999; 41(3): 175-7.
- Pedersen ME, Baldwin RA, Niquet J, Stafford GI, Van Staden J, Wasterlain CG and Jäger AK: Anticonvulsant effects of *Searsia dentata* (Anacardiaceae) leaf extract in rats. *Phytother Res* 2010; 24(6): 924-7.
- Toscano CD, Kingsley PJ, Marnett LJ and Bosetti F: NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. *Neurotoxicology* 2008; 29(6): 1114-20.
- Lowe IP, Robins E and Eyerman GS: The fluorimetric measurement of glutamic decarboxylase measurement and its distribution in brain. *J Neuro Chem* 1958; 3: 8-18.
- Govardhan P, Bandari J, Bandari S and Kumar P: *In-vitro* evaluation of effect of *Cassipouita filiformis* L. extracts on brain neurotransmitters in albino rats. *J of Sci* 2011; 1(1): 21-25.
- Das MK, Mazumder PM and Das S: Antiepileptic activity of methanol extract of *Butea monosperma* (Lam.) kuntze and its isolated bioactive compound in experimentally induced convulsion in swiss albino mice. *IJPSR* 2015; 7(12): 1066-72.
- Puri MM, Kumar L, Vishwakarma PD and Bahera D: Seizures with single therapeutic dose of Isoniazid. *Indian J Tuberc* 2012; 59: 100-02.
- Webster RA: Neurotransmitters, drugs, and brain function. Chichester: John Wiley and Sons Ltd; 2001; Chap 16: 325-50.
- Krishnakumar A: Dealing with epilepsy. *Frontline* 2000; 17(21): 14-27.
- Steven CS, Patricia O and Joseph IS: What Causes Epilepsy and Seizures? *Epilepsy Foundation* 2013.
- Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. *Epilepsia* 1989; 30: 389-99.
- Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epilepsy syndromes *Epilepsia* 1981; 30(4): 389-99.
- Bertrand D, Picard F, Le Hellard S, Weiland S, Farve I and Phillips H: How mutations in the nAChRs can cause ADNFLE epilepsy. *Epilepsia* 2002; 43(5): 112-22.
- Loiseau P, Duché B and Cordova S: Prognosis of benign childhood epilepsy with centrotemporal spikes. A follow-up of 168 patients. *Epilepsia* 1988; 29: 229-35.

### How to cite this article:

Geetha KM, Vishnupriya K, Jaferi F and Murugan V: Preliminary phytochemical investigations and antiepileptic activity of *Trema orientalis* (Linn.) extracts. *Int J Pharm Sci & Res* 2019; 10(8): 3957-62. doi: 10.13040/IJPSR.0975-8232.10(8).3957-62.